Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Joep J de JongHans StoopDaan NieboerJoost L BoormansG J L H Geert van LeendersPublished in: Histopathology (2018)
Urothelial bladder cancer patients showed fair agreement of PD-L1 assay outcome in cystectomies and matched TURB or lymph node specimens. PD-L1 expression was discordant more often after neoadjuvant therapy. Therefore, immune-checkpoint inhibitor studies should take into account specimen type and neoadjuvant therapy in assessing the predictive value of PD-L1 expression.
Keyphrases
- lymph node
- rectal cancer
- end stage renal disease
- ejection fraction
- locally advanced
- high grade
- chronic kidney disease
- newly diagnosed
- neoadjuvant chemotherapy
- urinary tract
- prognostic factors
- high throughput
- sentinel lymph node
- stem cells
- patient reported outcomes
- squamous cell carcinoma
- early stage
- mesenchymal stem cells
- cell therapy
- replacement therapy